



Integra LifeSciences to Host Analyst Forum On November 21, 2006

PLAINSBORO, N.J., Nov. 17, 2006 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will host an Analyst Forum on Tuesday, November 21, 2006 at 3:00 PM Eastern Time at the New York Marriott East Side Hotel in New York City. The meeting will be hosted by Stuart Essig, Integra LifeSciences' President and Chief Executive Officer. Integra's senior clinical, research, and sales personnel will lead presentations on the products that are expected to drive future sales growth and will provide an update on the multi-center clinical trial of the DuraGen Plus[®] product as an adhesion barrier in spinal surgery. A question and answer session will follow the formal presentations.

The Analyst Forum is open to all analysts and investors. Access to the live presentations will be available by dialing (913) 981-4911 or through a listen-only webcast via a link provided on the investor relations home page of our website at www.Integra-LS.com. Listeners participating via telephone or webcast will not be able to ask questions during the question and answer session.

A replay of the Analyst Forum will be accessible starting one hour following the live event. Access to the replay will be available through December 5, 2006 by dialing (719) 457-0820 (access code 5038043) or through the webcast accessible on the investor relations home page of our website.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.Integra-LS.com>.

Statements made in the upcoming Analyst Forum may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, and expected sales and potential therapeutic applications of new products. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President,
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com
John Bostjancic, Vice President of Corporate Development
and Investor Relations
(609) 936-2239
jbostjancic@Integra-LS.com